Samaritan Pharma

Samaritan Pharmaceuticals is a biopharmaceutical company that was primarily focused on the development of treatments for HIV, Alzheimer's disease, and cancer. The company's lead candidate, SP-01A, was an oral HIV-1 protease inhibitor that reached Phase 3 clinical trials. Another significant program was Caprospinol (SP-233), a small molecule aimed at treating Alzheimer's disease by preventing beta-amyloid toxicity and restoring mitochondrial function. Despite early clinical progress and various academic collaborations, the company's development pipeline has been largely inactive for several years. Samaritan was publicly traded on the OTC market under the symbol SPHC but has faced regulatory challenges and a cessation of financial reporting.